<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711436248</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711436248</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Peripheral Arterial Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Abdominal Obesity is Associated With a Lower Ankle–Brachial Index in Women With Polycystic Ovary Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dogan</surname>
<given-names>Mustafa Inanc</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436248">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tasci</surname>
<given-names>Ilker</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436248">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711436248"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bulucu</surname>
<given-names>Fatih</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436248">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aydogdu</surname>
<given-names>Aydogan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319711436248">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Acar</surname>
<given-names>Ramazan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436248">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ceyhan</surname>
<given-names>Temel</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319711436248">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Koc</surname>
<given-names>Bayram</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436248">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Demir</surname>
<given-names>Orhan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436248">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gezer</surname>
<given-names>Mustafa</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436248">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sağlam</surname>
<given-names>Kenan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436248">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711436248"><label>1</label>Department of Internal Medicine, Gulhane School of Medicine, Ankara, Turkey</aff>
<aff id="aff2-0003319711436248"><label>2</label>Department of Endocrinology and Metabolism, Gulhane School of Medicine, Ankara, Turkey</aff>
<aff id="aff3-0003319711436248"><label>3</label>Department of Obstetrics and Gynecology, Gulhane School of Medicine, Ankara, Turkey</aff>
<author-notes>
<corresp id="corresp1-0003319711436248">Ilker Tasci, GATA Ic Hastaliklari Bilim Dali, Etlik 06018 Ankara, Turkey Email: <email>ilkertasci@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>2</issue>
<fpage>105</fpage>
<lpage>111</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Polycystic ovary syndrome (PCOS) was linked to increased lifetime risk of cardiovascular disease. A low ankle–brachial index (ABI) is associated with accelerated atherosclerosis. The ABI value and the associated conditions in women with PCOS were searched in the present study. The ABI was measured using a handheld Doppler device and calculated using both standard and modified definitions. Women with PCOS (n = 103, mean age = 24.9 ± 5.9 years) had a mean ABI of 1.10 ± 0.10. A low ABI (≤0.9) was 2.9% and 14.6% using the standard and modified definitions, respectively. Mean ABI correlated negatively to body weight, BMI, waist circumference, waist-to-hip ratio, and hematocrit. Logistic regression analysis revealed higher waist-to-hip ratio as independently associated with a lower ABI. Frequency of ABI ≤0.9 in PCOS was lower than the general population. However, increased waist-to-hip ratio was a predictor of a lower ABI value.</p>
</abstract>
<kwd-group>
<kwd>polycystic ovary syndrome</kwd>
<kwd>ankle–brachial index</kwd>
<kwd>peripheral arterial disease</kwd>
<kwd>central obesity</kwd>
<kwd>waist-to-hip ratio</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711436248">
<title>Introduction</title>
<p>Polycystic ovary syndrome (PCOS) is a clinical entity of women characterized by oligomenorrhea, amenorrhea, and hyperandrogenism, affecting 4.8% to 8% of women in reproductive age.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711436248">1</xref>
</sup> It is one of the most commonly encountered endocrinopathies in women, resulting in significant infertility due to oligoanovulation. Clinical manifestations of PCOS include menstrual irregularity, infertility, hirsutism, acne, and obesity.</p>
<p>Although etiopathogenesis of PCOS is still obscure, insulin resistance has been considered as the leading disorder in the development of the disease.<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436248">2</xref>
</sup> An increased risk of dyslipidemia, diabetes mellitus, and cardiovascular disease (CVD) related to obesity and insulin resistance has been reported in these patients.<sup>
<xref ref-type="bibr" rid="bibr3-0003319711436248">3</xref>
<xref ref-type="bibr" rid="bibr4-0003319711436248"/>–<xref ref-type="bibr" rid="bibr5-0003319711436248">5</xref>
</sup> Besides, in a large meta-analysis, 2-fold increased risk of atherosclerosis was reported in women with PCOS compared to those without, independently from the body mass index (BMI).<sup>
<xref ref-type="bibr" rid="bibr6-0003319711436248">6</xref>
</sup>
</p>
<p>Peripheral arterial disease (PAD) is one of the major types of CVDs along with coronary heart disease (CHD), cerebrovascular disease, and aorta atherosclerosis/aneurysm.<sup>
<xref ref-type="bibr" rid="bibr7-0003319711436248">7</xref>
</sup> In a study conducted between 1999 and 2004 in North America, insulin resistance was suggested as an independent risk factor for the development of PAD.<sup>
<xref ref-type="bibr" rid="bibr8-0003319711436248">8</xref>
</sup> Peripheral arterial disease can successfully be diagnosed by noninvasive ankle–brachial index (ABI) test, which is effective in both making the diagnosis and determining the severity of the disease.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711436248">9</xref>
</sup> It was demonstrated that a low ABI (≤0.9) has a sensitivity of 79% to 95% and a specificity of 85% to 100% for the diagnosis of PAD.<sup>
<xref ref-type="bibr" rid="bibr10-0003319711436248">10</xref>
</sup> Although women with PCOS are prone to have most of the metabolic disorders related to atherosclerosis, data regarding its association to a higher risk of CVD are limited.<sup>
<xref ref-type="bibr" rid="bibr11-0003319711436248">11</xref>
</sup> Therefore, we aimed to assess the frequency of a low ABI and associated conditions in women with PCOS.</p>
</sec>
<sec id="section2-0003319711436248" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-0003319711436248">
<title>Research Type and Participant Selection</title>
<p>This cross-sectional and observational study was approved by the local ethics committee of Gulhane School of Medicine. Participants with PCOS were selected among the outpatients attending to endocrinology and gynecology clinics of the institution, between May 2010 and April 2011. Inclusion criteria were having PCOS diagnosis based on the Rotterdam criteria,<sup>
<xref ref-type="bibr" rid="bibr12-0003319711436248">12</xref>
</sup> being between the ages of 18 and 45, and signing the informed consent. Exclusion criteria were having proven CHD, stroke, heart failure, PAD, diabetes mellitus, and refusing to be a participant in the study. An informed consent was obtained from each participant.</p>
</sec>
<sec id="section4-0003319711436248">
<title>Basic Procedures</title>
<p>Family history of CVD in the first-degree relatives, smoking, and any of the past or current diseases and medications were noted. Blood pressure, height, weight, BMI, waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR) were determined for all participants. Hemoglobin, hematocrit, white blood cell count, platelet count, mean platelet volume, fasting plasma glucose, urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, albumin, calcium, vitamin B12, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) blood levels were also recorded.</p>
</sec>
<sec id="section5-0003319711436248">
<title>Measurement of ABI</title>
<p>The technique described by Grenon et al was used for the ABI test.<sup>
<xref ref-type="bibr" rid="bibr13-0003319711436248">13</xref>
</sup> The measurement was performed with the patient supine. To ensure the comfort of the arms, 2 metal armrests of 20 cm width were placed on the head of the stretcher at an angel of 30°. For the measurement, 4 fully calibrated aneroid sphygmomanometers with velcro cuffs were used (ERKA, D-83646, Germany). Cuff width was 12 cm and cuff length was 29 to 40 cm. Four extremities of the participant were wrapped with cuffs at the same time and, during this process the participant was allowed to rest at least for 5 minutes. Both of the brachial pulses in the upper extremities and dorsalis pedis and tibialis posterior pulses in the lower extremities were recorded. Measurements were obtained using a handheld 8-MHz Doppler instrument (Hadeco, Japan) using transducer gel. The first blood flow sound heard as the cuff was deflated was recorded. The readings were started from the right arm, followed by the right ankle, left ankle and left arm. The cycle was repeated and 2 values were recorded for each vessel. Mean value of the 2 measurements was considered as the final result for the respective vessel.</p>
</sec>
<sec id="section6-0003319711436248">
<title>Standard and Modified ABI Calculations</title>
<p>Standard ABI was calculated based on the Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease (TASC) II guidelines.<sup>
<xref ref-type="bibr" rid="bibr10-0003319711436248">10</xref>
</sup> First, right and left ABIs were calculated separately by dividing the higher systolic blood pressures in each ankle (a tibialis posterior or a dorsalis pedis) to the higher brachial systolic blood pressure measured in the right or left upper limbs. Then, the lower one of the right or left ABI values was considered as the final standard ABI value of the tested individual. Modified ABI was calculated by taking the lower readings, instead of the higher ones, at each ankle, still divided by the higher brachial pressure.<sup>
<xref ref-type="bibr" rid="bibr14-0003319711436248">14</xref>
</sup>
</p>
</sec>
<sec id="section7-0003319711436248">
<title>Statistics</title>
<p>Commercially available software was used for the statistical analyses (SPSS version 15.0, SPSS Inc, Chicago, Illinois). Mann-Whitney <italic>U</italic>, Kruskal-Wallis, Pearson-Rho correlation, and linear regression analysis tests were performed. The results of continuous variables were expressed as mean ± standard deviation. Two-sided <italic>P</italic> values &lt;.05 were accepted as significant.</p>
</sec>
</sec>
<sec id="section8-0003319711436248">
<title>Results</title>
<sec id="section9-0003319711436248">
<title>Demographics, Existing Clinical Diseases, and Basic Laboratory Data</title>
<p>A total of 103 women with PCOS aged between 18 and 42 years were included in the study. One participant had hypertension and 4 others had dyslipidemia. <xref ref-type="table" rid="table1-0003319711436248">Table 1</xref> shows the characteristics of the participants. The mean age was 24.9 ± 5.9 years. Mean height and weight were 163.6 ± 5.4 cm and 65.5 ± 14.1 kg, respectively. Mean BMI, WC, and HC were 24.4 ± 5.0 cm, 81.2 ± 13.0 cm, and 103.9 ± 11.0 cm, respectively. Mean WHR was 0.78 ± 0.06. Basic laboratory data are shown in <xref ref-type="table" rid="table2-0003319711436248">Table 2</xref>.</p>
<table-wrap id="table1-0003319711436248" position="float">
<label>Table 1.</label>
<caption>
<p>Demographics and Anthropometrics of the Participants</p>
</caption>
<graphic alternate-form-of="table1-0003319711436248" xlink:href="10.1177_0003319711436248-table1.tif"/>
<table>
<thead>
<tr>
<th>Parameter (n = 103)</th>
<th>Mean ± SD</th>
<th>Min–max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>24.9 ± 5.9</td>
<td>18-42</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>163.6 ± 5.4</td>
<td>148-180</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>65.5 ±14.1</td>
<td>44.4-110</td>
</tr>
<tr>
<td>Body mass index</td>
<td>24.4 ± 5.0</td>
<td>17.6-39.0</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>81.2 ± 13.0</td>
<td>58-117</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>103.9 ± 11.0</td>
<td>82-140</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.78 ± 0.06</td>
<td>0.64-0.94</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-0003319711436248" position="float">
<label>Table 2.</label>
<caption>
<p>Basic Laboratory Data</p>
</caption>
<graphic alternate-form-of="table2-0003319711436248" xlink:href="10.1177_0003319711436248-table2.tif"/>
<table>
<thead>
<tr>
<th>Parameter (n = 103)</th>
<th>Mean ± SD</th>
<th>Min–max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin, g/dL</td>
<td>13.1 ± 1.2</td>
<td>9.7-15.9</td>
</tr>
<tr>
<td>Hematocrit, %</td>
<td>38.5 ± 3.3</td>
<td>29.2-47.4</td>
</tr>
<tr>
<td>WBC, ×10<sup>3</sup>/µL</td>
<td>7.10 ± 1.82</td>
<td>2.90-12.90</td>
</tr>
<tr>
<td>Platelets, ×10<sup>3</sup>/µL</td>
<td>277 ± 64</td>
<td>160-440</td>
</tr>
<tr>
<td>Mean platelet volume, fL</td>
<td>8.22 ± 1.01</td>
<td>6.10-10.90</td>
</tr>
<tr>
<td>FPG, mg/dL</td>
<td>88 ± 8</td>
<td>59-110</td>
</tr>
<tr>
<td>Urea, mg/dL</td>
<td>23.6 ±13.0</td>
<td>12-129</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.84 ± 0.09</td>
<td>0.67-1.06</td>
</tr>
<tr>
<td>AST, U/L</td>
<td>19 ± 5</td>
<td>10-46</td>
</tr>
<tr>
<td>ALT, U/L</td>
<td>17 ±11</td>
<td>6-83</td>
</tr>
<tr>
<td>GGT, U/L</td>
<td>16 ± 8</td>
<td>7-44</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>185 ± 37</td>
<td>126-301</td>
</tr>
<tr>
<td>Triglyceride, mg/dL</td>
<td>113 ± 72</td>
<td>38-552</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>59 ± 14</td>
<td>34-111</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>104 ± 29</td>
<td>51-169</td>
</tr>
<tr>
<td>Albumin, g/dL</td>
<td>4.4 ± 0.3</td>
<td>3.8-5.0</td>
</tr>
<tr>
<td>Calcium, mg/dL</td>
<td>9.8 ± 0.5</td>
<td>8.0-10.9</td>
</tr>
<tr>
<td>Vitamin B12, pg/mL</td>
<td>212 ± 86</td>
<td>2.5-437</td>
</tr>
<tr>
<td>FSH, mIU/mL</td>
<td>5.48 ± 2.26</td>
<td>0.30-11.73</td>
</tr>
<tr>
<td>LH, mIU/mL</td>
<td>7.38 ± 5.68</td>
<td>0.10-30.47</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711436248">
<p>Abbreviations: WBC, white blood cell count; FPG, fasting plasma glucose; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FSH, follicle-stimulating hormone; LH, luteinizing hormone; SD, standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-0003319711436248">
<title>Frequency of a Low ABI</title>
<p>Mean ABI was 1.10 ± 0.10, and a low ABI (≤0.9) was found in 3 (2.9%) participants (<xref ref-type="table" rid="table3-0003319711436248">Table 3</xref>). According to the modified calculation, mean ABI was 1.02 ± 0.11 and a low ABI was detected in 15 (14.5%) participants. Modified ABI calculation has the advantage of detecting more people at risk of atherosclerotic disease but it may overestimate the prevalence of PAD.<sup>
<xref ref-type="bibr" rid="bibr15-0003319711436248">15</xref>
</sup> This was adapted to the design of the present work because the primary purpose of the study was to determine the distribution of ABI values and related factors in patients with PCOS, rather than detecting true prevalence of PAD in such a young population. Accordingly, although it was not confirmed by alternative tests, almost 15% of PAD prevalence was not likely in women younger than the age of 45, but it indicated that significant proportion of our study group had the risk of early atherosclerosis.</p>
<table-wrap id="table3-0003319711436248" position="float">
<label>Table 3.</label>
<caption>
<p>Ankle–Brachial Index (ABI) Values According to 2 Different Calculations<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table3-0003319711436248" xlink:href="10.1177_0003319711436248-table3.tif"/>
<table>
<thead>
<tr>
<th>ABI (n = 103)</th>
<th>Mean ± SD</th>
<th>Min–max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard</td>
<td>1.10 ± 0.10</td>
<td>0.82-1.32</td>
</tr>
<tr>
<td>Modified </td>
<td>1.02 ± 0.11</td>
<td>0.64-1.23</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319711436248">
<p>
<sup>a</sup> Standard ABI was calculated by dividing the highest right and left ankle readings to the highest one of brachial systolic blood pressures, while the lowest of the right or left ankle readings was used for modified ABI. The lower of right or left ABIs was considered as the final ABI value in each case.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0003319711436248">
<title>Associations of ABI in Women With PCOS</title>
<p>Number of smokers or ex-smokers was 20 (19%) in the study group. Smoking status did not bring out a significant difference in ABI values among the patients, either through standard or modified calculations (<xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>). Family history of CVD was present in 28 women (27.2%). Mean standard ABI value was 1.07 ± 0.11 and 1.12 ± 0.10 in participants with and without a family history of CVD (<italic>P</italic> = .020; <xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>). This finding suggested that women with PCOS having evidence of CVD in their first-degree relatives could have lower ABI values as compared to those without such a record. This data was also tested for the modified ABI, which also yielded lower ABI values in participants with a history of familial CVD (0.99 ± 0.13 vs 1.04 ± 0.10). However, the difference here did not reach significance (<xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>).</p>
<table-wrap id="table4-0003319711436248" position="float">
<label>Table 4.</label>
<caption>
<p>Association of ABI With Tested Parameters in Women With PCOS</p>
</caption>
<graphic alternate-form-of="table4-0003319711436248" xlink:href="10.1177_0003319711436248-table4.tif"/>
<table>
<thead>
<tr>
<th align="center" colspan="5">Standard ABI</th>
<th colspan="5">Modified ABI</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="2">Smokers<sup>a</sup>
</td>
<td colspan="2">Nonsmokers</td>
<td>
<italic>P</italic>
</td>
<td colspan="2">Smokers</td>
<td colspan="2">Nonsmokers</td>
<td>
<italic>P</italic>
</td>
</tr>
<tr>
<td colspan="2">1.09 ± 0.09</td>
<td colspan="2">1.11 ± 0.10</td>
<td>.380</td>
<td colspan="2">1.00 ± 0.09</td>
<td align="center" colspan="2">1.030 ± 0.11</td>
<td>.132</td>
</tr>
<tr>
<td colspan="2">CVD family history (+)<sup>b</sup>
</td>
<td align="center" colspan="2">CVD family history (−)</td>
<td>
</td>
<td align="center" colspan="2">CVD family history (+)</td>
<td align="center" colspan="2">CVD family history (−)</td>
<td>
</td>
</tr>
<tr>
<td colspan="2">1.07 ± 0.11</td>
<td colspan="2">1.12 ± 0.10</td>
<td>.020</td>
<td colspan="2">0.99 ± 0.13</td>
<td colspan="2">1.04 ± 0.10</td>
<td>.084</td>
</tr>
<tr>
<td colspan="2">BMI &lt;25<sup>c</sup>
</td>
<td align="center" colspan="2">BMI ≥25</td>
<td>
</td>
<td align="center" colspan="2">BMI &lt;25<sup>c</sup>
</td>
<td align="center" colspan="2">BMI ≥25</td>
<td>
</td>
</tr>
<tr>
<td colspan="2">1.12 ± 0.09</td>
<td colspan="2">1.08 ± 0.11</td>
<td>.020</td>
<td colspan="2">1.04 ± 0.10</td>
<td colspan="2">0.99 ± 0.12</td>
<td>
<italic>.028</italic>
</td>
</tr>
<tr>
<td colspan="2">WC ≥88 cm<sup>d</sup>
</td>
<td align="center" colspan="2">WC &lt;88 cm</td>
<td>
</td>
<td align="center" colspan="2">WC ≥88 cm</td>
<td align="center" colspan="2">WC &lt;88 cm</td>
<td> </td>
</tr>
<tr>
<td colspan="2">1.07 ± 0.12</td>
<td colspan="2">1.12 ± 0.09</td>
<td>.020</td>
<td colspan="2">0.99 ± 0.13</td>
<td colspan="2">1.04 ± 0.09</td>
<td>
<italic>.043</italic>
</td>
</tr>
<tr>
<td colspan="2">WHR &gt;0.8<sup>e</sup>
</td>
<td align="center" colspan="2">WHR ≤0.8</td>
<td>
</td>
<td align="center" colspan="2">WHR &gt;0.8</td>
<td align="center" colspan="2">WHR ≤0.8</td>
<td>
</td>
</tr>
<tr>
<td colspan="2">1.07 ± 0.11</td>
<td colspan="2">1.13 ± 0.09</td>
<td>.010</td>
<td colspan="2">0.98 ± 0.12</td>
<td colspan="2">1.05 ± 0.09</td>
<td>
<italic>.001</italic>
</td>
</tr>
<tr>
<td colspan="2">3 PCOS criteria<sup>f</sup>
</td>
<td align="center" colspan="2">2 PCOS criteria</td>
<td>
</td>
<td align="center" colspan="2">3 PCOS criteria</td>
<td align="center" colspan="2">2 PCOS criteria</td>
<td>
</td>
</tr>
<tr>
<td colspan="2">1.12 ± 0.09</td>
<td colspan="2">1.10 ± 0.10</td>
<td>.684</td>
<td colspan="2">1.05 ± 0.09</td>
<td colspan="2">1.01 ± 0.12</td>
<td>.347</td>
</tr>
<tr>
<td align="center" colspan="4">CVD risk category</td>
<td>
</td>
<td align="center" colspan="4">CVD risk category</td>
<td>
</td>
</tr>
<tr>
<td>Low</td>
<td align="center" colspan="2">Moderate</td>
<td align="center">High</td>
<td>
</td>
<td align="center">Low</td>
<td align="center" colspan="2">Moderate</td>
<td align="center">High</td>
<td>
</td>
</tr>
<tr>
<td>1.12 ± 0.10</td>
<td colspan="2">1.02 ± 0.10</td>
<td>1.08 ± 0.07</td>
<td>.019</td>
<td>1.03 ± 0.11</td>
<td colspan="2">0.94 ± 0.13</td>
<td>1.02 ± 0.05</td>
<td>.037</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319711436248">
<p>Abbreviations: ABI, ankle–brachial index; CVD, cardiovascular disease; BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio; PCOS, polycystic ovary syndrome.</p>
</fn>
<fn id="table-fn4-0003319711436248">
<p>Numbers of CVD risk factors present; “low”: 0 to 1 risk factors (n = 88), “moderate”: 2 risk factors (n = 10), “high”: ≥3 risk factors (n = 5). Low versus moderate risk group; <italic>P</italic> = .007 for standard and <italic>P</italic> = .014 for modified calculation; low- versus high-risk group <italic>P</italic> = .310 for standard and <italic>P</italic> = .014 for modified calculation (<italic>P</italic> = .402).</p>
</fn>
<fn id="table-fn5-0003319711436248">
<p>
<sup>a</sup> Number/ratio of smokers: 20 (19%).</p>
</fn>
<fn id="table-fn6-0003319711436248">
<p>
<sup>b</sup> Family history of CVD present: 28 (27.2%).</p>
</fn>
<fn id="table-fn7-0003319711436248">
<p>
<sup>c</sup> BMI ≥25: 36 (35%).</p>
</fn>
<fn id="table-fn8-0003319711436248">
<p>
<sup>d</sup> Waist circumference ≥88 cm: 32 (31%).</p>
</fn>
<fn id="table-fn9-0003319711436248">
<p>
<sup>e</sup> WHR &gt;0.8: 38 (37%).</p>
</fn>
<fn id="table-fn10-0003319711436248">
<p>
<sup>f</sup> Three PCOS criteria present: 31 (30.1%).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The participants were divided into 2 groups as having BMI ≥25 and &lt;25, and 36 (35%) participants had a high BMI. Mean ABI in women with a BMI &lt;25 was significantly higher either through the standard calculation (<italic>P</italic> = .020) or through the modified one (<italic>P</italic> = .028; <xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>). Patients were also divided into 2 according to their WC as ≥88 and &lt;88 cm. Of them, 32 (31%) individuals had increased WC and significantly lower ABI values according to both the standard (<italic>P</italic> = .020) and modified (<italic>P</italic> = .043) calculations (<xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>). When participants were categorized according to WHR using a threshold of ≤0.8 that is acceptable for women,<sup>
<xref ref-type="bibr" rid="bibr16-0003319711436248">16</xref>
</sup> those 38 (37%) women with WHR &gt;0.8 had significantly lower mean ABI compared with those with a WHR ≤0.8, according to both calculations (<italic>P</italic> = .010 and <italic>P</italic> = .001, respectively; <xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>).</p>
<p>Participants were divided into 2 groups according to the number of diagnostic criteria for PCOS they had at the time of diagnosis, assuming that those with all 3 Rotterdam criteria could have a more “established” or “severe” disease in terms of metabolic consequences, compared with those having only 2 criteria. According the 2003 revised Rotterdam consensus,<sup>
<xref ref-type="bibr" rid="bibr12-0003319711436248">12</xref>
</sup> 2 of the 3 criteria had to be met to fit the definition of PCOS: chronic anovulation, clinical, and/or biochemical evidence of hyperandrogenism and polycystic ovaries. In our study, 31 (30.1%) patients had 3 and 72 (69.9%) had 2 criteria; however, the mean ABI value did not differ in these 2 subsets (<xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>).</p>
<p>Finally, the participants were classified as “low,” “moderate,” and “high” risk, according to the number of established cardiovascular risk factors present. These were smoking, family history of CVD, dyslipidemia, and obesity (BMI ≥30). Individuals with 0 or 1 risk factor has been considered carrying low risk, while those having 3 or more are accepted as high risk.<sup>
<xref ref-type="bibr" rid="bibr7-0003319711436248">7</xref>,<xref ref-type="bibr" rid="bibr17-0003319711436248">17</xref>
</sup>. Patient numbers were 88, 10, and 5 in low-, moderate-, and high-risk categories, respectively. We observed that the mean ABI values were significantly different across these 3 categories, according to both standard (<italic>P</italic> = .019) and modified (<italic>P</italic> = .037) calculations (<xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>). When low- and moderate-risk groups were compared, the standard and modified ABI values were significantly higher in the low-risk participants than those with a moderate risk (<italic>P</italic> = .007 and <italic>P</italic> = .014 for standard and modified calculations, respectively). No significant difference was observed with respect to ABI in low- versus high-risk groups and moderate- versus high-risk groups (<xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>), but the patient numbers in moderate- and high-risk categories were quite low.</p>
</sec>
<sec id="section12-0003319711436248">
<title>Correlation and Multiple Regression Analyses</title>
<p>Correlation of standard and modified ABI to the parameters studied (age, height, weight, BMI, WC, HC, WHR, hemoglobin, hematocrit, WBC, platelet counts, mean platelet volume, serum fasting glucose, urea, creatinine, AST, ALT, GGT, total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, albumin, calcium, vitamin B12, FSH, and LH levels) was tested by Pearson analysis. Standard ABI values correlated negatively to body weight, BMI, WC, WHR, and hematocrit (<xref ref-type="table" rid="table5-0003319711436248">Table 5</xref>), while modified ABI values also correlated negatively with WC and WHR (<xref ref-type="table" rid="table5-0003319711436248">Table 5</xref>). Besides, multiple logistic regression analysis revealed WHR as the independent predictor of lower ABI in women with PCOS, both for standard (adjusted <italic>R</italic>
<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436248">2</xref>
</sup> = .099, β = −.330, <italic>P</italic> = .001) and modified (adjusted <italic>R</italic>
<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436248">2</xref>
</sup> = .091, β = −.315, <italic>P</italic> = .001) calculations.</p>
<table-wrap id="table5-0003319711436248" position="float">
<label>Table 5.</label>
<caption>
<p>Significant Correlates of ABI in Women With PCOS</p>
</caption>
<graphic alternate-form-of="table5-0003319711436248" xlink:href="10.1177_0003319711436248-table5.tif"/>
<table>
<thead>
<tr>
<th rowspan="3">Parameter</th>
<th colspan="4">ABI</th>
</tr>
<tr>
<th colspan="2">Standard</th>
<th colspan="2">Modified</th>
</tr>
<tr>
<th>
<italic>r</italic>
</th>
<th>
<italic>P</italic>
</th>
<th>
<italic>r</italic>
</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight</td>
<td>−.228</td>
<td>.020</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>BMI</td>
<td>−.211</td>
<td>.032</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Waist circumference</td>
<td>−.266</td>
<td>.007</td>
<td>−.222</td>
<td>.024</td>
</tr>
<tr>
<td>WHR<sup>a</sup>
</td>
<td>−.300</td>
<td>.002</td>
<td>−.315</td>
<td>.001</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>−.247</td>
<td>.018</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0003319711436248">
<p>Abbreviations: ABI, ankle–brachial index; BMI, body mass index; PCOS, polycystic ovary syndrome; WHR, waist-to-hip ratio.</p>
</fn>
<fn id="table-fn12-0003319711436248">
<p>
<sup>a</sup> WHR was the only parameter independently associated with standard ABI value (adjusted <italic>R</italic>
<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436248">2</xref>
</sup> = .099, β = −.330, <italic>P</italic> = .001) and to modified ABI value (adjusted <italic>R</italic>
<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436248">2</xref>
</sup> = .091, β = −.315, <italic>P</italic> = .001) after regression analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section13-0003319711436248">
<title>Discussion</title>
<p>We observed a low ABI value only in 3 (2.9%) of 103 women with PCOS. On the other hand, ABI displayed significant associations with the major characteristics of the disease, suggesting that these participants are at risk of early atherosclerosis. We first calculated ABI as recommended by the TASC-II guidelines,<sup>
<xref ref-type="bibr" rid="bibr9-0003319711436248">9</xref>
</sup> which is compatible with the diagnosis of PAD. A recent national multicenter study on Turkish people over 50 years old revealed a 20% prevalence of a low ABI.<sup>
<xref ref-type="bibr" rid="bibr18-0003319711436248">18</xref>
</sup> However, considering the much younger age of the participants, the frequency of PAD by 2.9% in the present study also seems remarkable. To our knowledge, there is no previous data regarding low ABI frequency in a similar age population. Patients with PCOS are exposed to almost all atherosclerotic stimuli such as inflammation, insulin resistance, obesity, and dyslipidemia. However, our study confirms the previous notion that much longer time is needed for the development of occlusive plaques.</p>
<p>Ankle–brachial index was also calculated by a modified formula in the present work, using the lowest reading in the ankles. This time, 14.5% of the patients had ABI ≤0.9. Since this calculation method has not been approved by the guidelines, making a final diagnosis of PAD may simply overestimate its true prevalence. However, many cases at risk can be detected with this modified calculation, suggesting it may be more useful for screening purposes.<sup>
<xref ref-type="bibr" rid="bibr14-0003319711436248">14</xref>,<xref ref-type="bibr" rid="bibr15-0003319711436248">15</xref>
</sup> Therefore, our data suggest that participants with PCOS should be evaluated more carefully for early atherosclerosis.</p>
<p>Another aim of the present study was to determine the distribution of ABI values and related factors among women with PCOS. It was proven that ABI ≤0.9 indicates not only presence of occlusive artery disease of lower extremities but also a disseminated atherosclerotic state.<sup>
<xref ref-type="bibr" rid="bibr18-0003319711436248">18</xref><xref ref-type="bibr" rid="bibr19-0003319711436248"/>–<xref ref-type="bibr" rid="bibr20-0003319711436248">20</xref>
</sup> Furthermore, low ABI values seem to increase the risk of all-cause mortality and ABI &lt;1.10 was proposed to be the threshold value in this regard.<sup>
<xref ref-type="bibr" rid="bibr20-0003319711436248">20</xref>
</sup> In fact, ABI values between 0.91 and 0.99 were also described as low values.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711436248">9</xref>
</sup> In the Multi-Ethnic Study of Atherosclerosis (MESA) study, individuals with borderline (0.90-0.99) and low-normal (1.0-1.09) ABI values were found to have significantly higher level of subclinical atherosclerosis and CHD prevalence both in men and in women.<sup>
<xref ref-type="bibr" rid="bibr21-0003319711436248">21</xref>
</sup> The association between these ranges and overall death is stronger than that of ABI values in the normal range.<sup>
<xref ref-type="bibr" rid="bibr20-0003319711436248">20</xref>
</sup> Moreover, ABI &gt;1.4 confers a higher cardiovascular event risk, that is a high ABI was found to possess similar risk to that of a low ABI.<sup>
<xref ref-type="bibr" rid="bibr20-0003319711436248">20</xref>
</sup>
</p>
<p>The data related to the frequency of PAD diagnosed with ABI in genders are conflicting. Low ABI values were more frequent in women than in men in some studies.<sup>
<xref ref-type="bibr" rid="bibr22-0003319711436248">22</xref>,<xref ref-type="bibr" rid="bibr23-0003319711436248">23</xref>
</sup> On the other hand, some studies reported higher or equal frequency of a low ABI in men when compared with women.<sup>
<xref ref-type="bibr" rid="bibr18-0003319711436248">18</xref>,<xref ref-type="bibr" rid="bibr20-0003319711436248">20</xref>,<xref ref-type="bibr" rid="bibr24-0003319711436248">24</xref>
<xref ref-type="bibr" rid="bibr25-0003319711436248"/>–<xref ref-type="bibr" rid="bibr26-0003319711436248">26</xref> </sup>However, recent data pointed out women as having lower “normal” ABI values. As an example, a study reported that ABI values which may indicate presence of an atherosclerotic disease in women were 0.1 units lower than that of men (women &lt;1, men &lt;1.1).<sup>
<xref ref-type="bibr" rid="bibr21-0003319711436248">21</xref>
</sup> Similarly, women had 0.02 and 0.07 units lower ABI values compared with men in the MESA survey<sup>
<xref ref-type="bibr" rid="bibr27-0003319711436248">27</xref>
</sup> and the San Luis Valley Diabetes Study,<sup>
<xref ref-type="bibr" rid="bibr28-0003319711436248">28</xref>
</sup> respectively. Other studies also reported 0.03 and 0.05 lower mean ABI values in women.<sup>
<xref ref-type="bibr" rid="bibr25-0003319711436248">25</xref>,<xref ref-type="bibr" rid="bibr29-0003319711436248">29</xref>
</sup> Nevertheless, a lower threshold for ABI to diagnose PAD in women has not been defined, and whether almost 3% prevalence of PAD in our young participants was affected by this issue is not clear.</p>
<p>Although it is not clear whether atherosclerosis is accelerated in women with PCOS, several lines of evidence indicate high CVD risk in these individuals.<sup>
<xref ref-type="bibr" rid="bibr30-0003319711436248">30</xref>
</sup> First, diabetes mellitus, obesity, dyslipidemia, hypertension, and metabolic syndrome are more commonly encountered in participants with PCOS.<sup>
<xref ref-type="bibr" rid="bibr4-0003319711436248">4</xref>,<xref ref-type="bibr" rid="bibr31-0003319711436248">31</xref>,<xref ref-type="bibr" rid="bibr32-0003319711436248">32</xref>
</sup> Second, insulin resistance, high serum C-reactive protein, and endothelial dysfunction were shown to be frequent in these individuals.<sup>
<xref ref-type="bibr" rid="bibr33-0003319711436248">33</xref>
<xref ref-type="bibr" rid="bibr34-0003319711436248"/>–<xref ref-type="bibr" rid="bibr35-0003319711436248">35</xref>
</sup> Third, a recent study reported that arterial stiffness, a novel risk factor for future CVD,<sup>
<xref ref-type="bibr" rid="bibr36-0003319711436248">36</xref>
</sup> was more common in PCOS participants in their 20s.<sup>
<xref ref-type="bibr" rid="bibr37-0003319711436248">37</xref>
</sup> Fourth, carotid intima–media thickness was higher in women with PCOS<sup>
<xref ref-type="bibr" rid="bibr38-0003319711436248">38</xref>
</sup> and in women over 45 years with a history of PCOS.<sup>
<xref ref-type="bibr" rid="bibr39-0003319711436248">39</xref>
</sup> In the same study, no clue for clinical atherosclerosis could be detected in women with PCOS aged between 30 and 44 years. Finally, it was reported that there is an increased relative risk of CHD in these individuals when compared with women with similar age and weight.<sup>
<xref ref-type="bibr" rid="bibr40-0003319711436248">40</xref>
</sup> However, absolute risk may not be so high, and there are also phenotypical differences in individuals having the disease, which may determine CVD risk.<sup>
<xref ref-type="bibr" rid="bibr41-0003319711436248">41</xref>
</sup> Overall, these data along with our study which consisted of younger participants suggest that women with PCOS are exposed to a lifetime increased risk of atherosclerotic diseases.</p>
<p>The rate of carrying at least 1 cardiovascular risk factor was 45% in women with PCOS in a previous study.<sup>
<xref ref-type="bibr" rid="bibr42-0003319711436248">42</xref>
</sup> In the present study, we investigated whether ABI values were associated with the presence of established risk factors and found that mean ABI was significantly different among low-, moderate- and high-risk patients (<xref ref-type="table" rid="table4-0003319711436248">Table 4</xref>). However, patient numbers in the latter 2 categories were much lower, hindering accuracy of statistical analyses. On the other hand, increased cardiovascular risk in patients with PCOS cannot be explained by established risk factors.<sup>
<xref ref-type="bibr" rid="bibr43-0003319711436248">43</xref>
</sup> Moreover, all of the known major risk factors are not equal with respect to their strength in determining the risk. As an example, 30% of our participants had CVD family history, and these individuals had a lower mean ABI, suggesting that presence of such history may be clinically useful in determining the risk status of individuals with PCOS. Smoking had no correlation with the ABI values in the present study, which may be related to the fact that a longer time is required for smoking to accelerate atherosclerosis.</p>
<p>Central obesity, one of the components of the metabolic syndrome, is an independent predictor of future cardiovascular events.<sup>
<xref ref-type="bibr" rid="bibr44-0003319711436248">44</xref>
</sup> In the present study, ABI values obtained according to both standard and modified calculations were significantly lower in participants with BMI &gt;25. Body mass index was also negatively correlated with standard ABI. Ankle–brachial index was significantly lower in women with increased WC (&gt;88 cm), and WC correlated negatively to both standard and modified ABIs. These results which indicate negative relationships of ABI value with BMI and WC is novel and considered important. Moreover, mean ABI was also significantly lower in participants with increased WHR (&gt;0.8) that is accepted as a better measure of central obesity and strongly related to CVD risk.<sup>
<xref ref-type="bibr" rid="bibr16-0003319711436248">16</xref>,<xref ref-type="bibr" rid="bibr44-0003319711436248">44</xref>
</sup> Furthermore, a negative correlation was observed between WHR and both standard and modified ABIs. Importantly, logistic regression analysis revealed only WHR, but not WC or BMI, as the independent predictor of lower ABI values. Increased WC and WHR were recently associated with a higher prevalence of PAD<sup>
<xref ref-type="bibr" rid="bibr45-0003319711436248">45</xref>
<xref ref-type="bibr" rid="bibr46-0003319711436248"/>–<xref ref-type="bibr" rid="bibr47-0003319711436248">47</xref>
</sup>; however, a relation of central obesity to a measure of atherosclerosis was for the first time demonstrated in a young group of people by our investigation.</p>
<p>The management of women with PCOS with respect to CVD risk has not been defined. Identification of the patients carrying CVD risk, determination of follow-up, and administration of primary and secondary prevention measures where necessary were all recommended.<sup>
<xref ref-type="bibr" rid="bibr43-0003319711436248">43</xref>
</sup> However, none of the international societies for CVD has yet published any guidelines.</p>
<p>Several limitations to this pilot case–control study need to be acknowledged. Due to the young age of the participants and the multifactorial etiology of CVD, it cannot be concluded by the present study that PCOS is a definite cause of PAD or atherosclerotic events in affected individuals. Besides, since the number of participants remained considerably small due to narrow selection criteria, the results may not represent all women with PCOS who are known to display phenotypical differences. Finally, further investigations could not be performed in those 3 women with an ABI ≤0.9 to confirm the presence of occlusive disease in the lower limbs.</p>
<p>In conclusion, although a small proportion of women with PCOS were found to have an ABI ≤0.9 in the present study, those with a family history of CVD and those with central obesity had lower ABI values. Measurement of ABI may be useful in stratifying the risk of atherosclerotic diseases in these individuals. These data also support the notion that women with PCOS may early or more frequently experience atherosclerotic diseases.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711436248">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711436248">
<label>Funding</label>
<p>The authors received no financial support for the research, authorsship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711436248">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azziz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Reyna</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Key</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Knochenhauer</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Yildiz</surname>
<given-names>BO</given-names>
</name>
</person-group>. <article-title>The prevalence and features of the polycystic ovary syndrome in an unselected population</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>6</issue>):<fpage>2745</fpage>–<lpage>2749</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711436248">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeUgarte</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Bartolucci</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Azziz</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment</article-title>. <source>Fertil Steril</source>. <year>2005</year>;<volume>83</volume>(<issue>5</issue>):<fpage>1454</fpage>–<lpage>1460</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711436248">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legro</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Kunselman</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Dunaif</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome</article-title>. <source>Am J Med</source>. <year>2001</year>;<volume>111</volume>(<issue>8</issue>):<fpage>607</fpage>–<lpage>613</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711436248">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legro</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Kunselman</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Dodson</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Dunaif</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1999</year>;<volume>84</volume>(<issue>1</issue>):<fpage>165</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711436248">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaw</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Bairey Merz</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Azziz</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the national institutes of health--national heart, lung, and blood institute sponsored women's Ischemia syndrome evaluation</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>(<issue>4</issue>):<fpage>1276</fpage>–<lpage>1284</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711436248">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Groot</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Dekkers</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Romijn</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Dieben</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Helmerhorst</surname>
<given-names>FM</given-names>
</name>
</person-group>. <article-title>PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis</article-title>. <source>Hum Reprod Update</source>. <year>2011</year>;<volume>17</volume>(<issue>4</issue>):<fpage>495</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711436248">
<label>7</label>
<citation citation-type="journal">
<collab collab-type="author">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)</collab>. <article-title>Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>25</issue>):<fpage>3143</fpage>–<lpage>3421</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711436248">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pande</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Perlstein</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Beckman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Creager</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Association of insulin resistance and inflammation with peripheral arterial disease: the national health and nutrition examination survey, 1999 to 2004</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>118</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711436248">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norgren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hiatt</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Dormandy</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Inter-society consensus for the management of peripheral arterial disease (TASCII)</article-title>. <source>Eur J Vasc Endovasc Surg</source>. <year>2007</year>;<volume>33</volume>(<issue>suppl 1</issue>):<fpage>S1</fpage>–<lpage>S75</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711436248">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Haskal</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Hertzer</surname>
<given-names>NR</given-names>
</name>
<etal/>
</person-group>. <article-title>ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>47</volume>(<issue>6</issue>):<fpage>e1</fpage>–<lpage>e192</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711436248">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legro</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>Polycystic ovary syndrome and cardiovascular disease: a premature association?</article-title> <source>Endocr Rev</source>. <year>2003</year>;<volume>24</volume>(<issue>3</issue>):<fpage>302</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711436248">
<label>12</label>
<citation citation-type="journal">
<collab collab-type="author">Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</collab>. <article-title>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome</article-title>. <source>Fertil Steril</source>. <year>2004</year>;<volume>81</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711436248">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grenon</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hsiang</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Video in clinical medicine. Ankle-brachial index for assessment of peripheral arterial disease</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>(<issue>19</issue>):<fpage>e40</fpage>.</citation>
</ref>
<ref id="bibr14-0003319711436248">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Espinola-Klein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rupprecht</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Bickel</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>118</volume>(<issue>9</issue>):<fpage>961</fpage>–<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711436248">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schröder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Diehm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kareem</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>A modified calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial disease</article-title>. <source>J Vasc Surg</source>. <year>2006</year>;<volume>44</volume>(<issue>3</issue>):<fpage>531</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711436248">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>van Leer</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Seidell</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lean</surname>
<given-names>ME</given-names>
</name>
</person-group>. <article-title>Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample</article-title>. <source>BMJ</source>. <year>1995</year>;<volume>311</volume>(<issue>7017</issue>):<fpage>1401</fpage>–<lpage>1405</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711436248">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mancia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>De Backer</surname>
<given-names>G</given-names>
</name>
</person-group>, <article-title>Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>12</issue>):<fpage>1462</fpage>–<lpage>1536</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711436248">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bozkurt</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Tasci</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tabak</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gumus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Peripheral artery disease assessed by ankle-brachial index in patients with established cardiovascular disease or at least one risk factor for atherothrombosis-CAREFUL Study: a national, multi-center, cross-sectional observational study</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2011</year>;<volume>11</volume>:<fpage>4</fpage>.</citation>
</ref>
<ref id="bibr19-0003319711436248">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Menyar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rashdan</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Ankle-brachial index and extent of atherosclerosis in patients from the Middle East (the AGATHA-ME study): a cross-sectional multicenter study</article-title>. <source>Angiology</source>. <year>2009</year>;<volume>60</volume>(<issue>3</issue>):<fpage>329</fpage>–<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711436248">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Resnick</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>MM</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the strong heart study</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>6</issue>):<fpage>733</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711436248">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDermott</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Criqui</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group>. <article-title>Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis</article-title>. <source>Am J Epidemiol</source>. <year>2005</year>;<volume>162</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711436248">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Price</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Fowkes</surname>
<given-names>GF</given-names>
</name>
</person-group>. <article-title>Frequency of a low ankle brachial index in the general population by age, sex and deprivation: cross-sectional survey of 28,980 men and women</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source>. <year>2008</year>;<volume>15</volume>(<issue>3</issue>):<fpage>370</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711436248">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Sharrett</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Chambless</surname>
<given-names>LE</given-names>
</name>
<etal/>
</person-group>. <article-title>Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study</article-title>. <source>Atherosclerosis</source>. <year>1997</year>;<volume>131</volume>(<issue>1</issue>):<fpage>115</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711436248">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fowkes</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Tuta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kozak</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study</article-title>. <source>Eur Heart J</source>. <year>2006</year>;<volume>27</volume>(<issue>15</issue>):<fpage>1861</fpage>–<lpage>1867</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711436248">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoffers</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Rinkens</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Kester</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Knottnerus</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease</article-title>. <source>Int J Epidemiol</source>. <year>1996</year>;<volume>25</volume>(<issue>2</issue>):<fpage>282</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711436248">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Criqui</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Treat-Jacobson</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Peripheral arterial disease detection, awareness, and treatment in primary care</article-title>. <source>JAMA</source>. <year>2001</year>;<volume>286</volume>(<issue>11</issue>):<fpage>1317</fpage>–<lpage>1324</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711436248">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aboyans</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Criqui</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>McClelland</surname>
<given-names>RL</given-names>
</name>
<etal/>
</person-group>. <article-title>Intrinsic contribution of gender and ethnicity to normal ankle-brachial index values: the Multi-Ethnic Study of Atherosclerosis (MESA)</article-title>. <source>J Vasc Surg</source>. <year>2007</year>;<volume>45</volume>(<issue>2</issue>):<fpage>319</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711436248">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiatt</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Hoag</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamman</surname>
<given-names>RF</given-names>
</name>
</person-group>. <article-title>Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley diabetes study</article-title>. <source>Circulation</source>. <year>1995</year>;<volume>91</volume>(<issue>5</issue>):<fpage>1472</fpage>–<lpage>1479</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711436248">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fowkes</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Housley</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cawood</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Macintyre</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Ruckley</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Prescott</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population</article-title>. <source>Int J Epidemiol</source>. <year>1991</year>;<volume>20</volume>(<issue>2</issue>):<fpage>384</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711436248">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrmann</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>Polycystic ovary syndrome</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>12</issue>):<fpage>1223</fpage>–<lpage>1236</lpage>.</citation>
</ref>
<ref id="bibr31-0003319711436248">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elting</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Korsen</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Schoemaker</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2001</year>;<volume>55</volume>(<issue>6</issue>):<fpage>767</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr32-0003319711436248">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cussons</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Zimmet</surname>
<given-names>PZ</given-names>
</name>
<name>
<surname>Stuckey</surname>
<given-names>BG</given-names>
</name>
</person-group>. <article-title>Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome</article-title>. <source>Hum Reprod</source>. <year>2008</year>;<volume>23</volume>(<issue>10</issue>):<fpage>2352</fpage>–<lpage>2358</lpage>.</citation>
</ref>
<ref id="bibr33-0003319711436248">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burghen</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Givens</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Kitabchi</surname>
<given-names>AE</given-names>
</name>
</person-group>. <article-title>Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1980</year>;<volume>50</volume>(<issue>1</issue>):<fpage>113</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr34-0003319711436248">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makedos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goulis</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Papanikolaou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Panidis</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study</article-title>. <source>Angiology</source>. <year>2010</year>;<volume>61</volume>(<issue>6</issue>):<fpage>595</fpage>–<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr35-0003319711436248">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarkun</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Arslan</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Cantürk</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Türemen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>11</issue>):<fpage>5592</fpage>–<lpage>5596</lpage>.</citation>
</ref>
<ref id="bibr36-0003319711436248">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Vasan</surname>
<given-names>RS</given-names>
</name>
<etal/>
</person-group>. <article-title>Arterial stiffness and cardiovascular events: the Framingham heart study</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>(<issue>4</issue>):<fpage>505</fpage>–<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr37-0003319711436248">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dessapt-Baradez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sivakumar</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Circulating vascular progenitor cells and central arterial stiffness in polycystic ovary syndrome</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>5</issue>):<fpage>e20317</fpage>.</citation>
</ref>
<ref id="bibr38-0003319711436248">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ercan</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Ertek</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Is</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Factors associated with increased carotid intima-media thickness and being nondipper in nonobese and normotensive young patients affected by PCOS</article-title>. <source>Angiology</source>. <year>2011</year>;<volume>62</volume>(<issue>7</issue>):<fpage>543</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr39-0003319711436248">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Talbott</surname>
<given-names>EO</given-names>
</name>
<name>
<surname>Guzick</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Sutton-Tyrrell</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2000</year>;<volume>20</volume>(<issue>11</issue>):<fpage>2414</fpage>–<lpage>2421</lpage>.</citation>
</ref>
<ref id="bibr40-0003319711436248">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solomon</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>FB</given-names>
</name>
<name>
<surname>Dunaif</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Menstrual cycle irregularity and risk for future cardiovascular disease</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2002</year>;<volume>87</volume>(<issue>5</issue>):<fpage>2013</fpage>–<lpage>2017</lpage>.</citation>
</ref>
<ref id="bibr41-0003319711436248">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daskalopoulos</surname>
<given-names>GN</given-names>
</name>
<name>
<surname>Karkanaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Karagiannis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
</person-group>. <article-title>Is the risk for cardiovascular disease increased in all phenotypes of the polycystic ovary syndrome?</article-title> <source>Angiology</source>. <year>2011</year>;<volume>62</volume>(<issue>4</issue>):<fpage>285</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr42-0003319711436248">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carmina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Rini</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2005</year>;<volume>90</volume>(<issue>5</issue>):<fpage>2545</fpage>–<lpage>2549</lpage>.</citation>
</ref>
<ref id="bibr43-0003319711436248">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wild</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Carmina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Diamanti-Kandarakis</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) society</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2010</year>;<volume>95</volume>(<issue>5</issue>):<fpage>2038</fpage>–<lpage>2049</lpage>.</citation>
</ref>
<ref id="bibr44-0003319711436248">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Czernichow</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kengne</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Stamatakis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Batty</surname>
<given-names>GD</given-names>
</name>
</person-group>. <article-title>Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies</article-title>. <source>Obes Rev</source>. <year>2011</year>;<volume>12</volume>(<issue>9</issue>):<fpage>680</fpage>–<lpage>687</lpage>.</citation>
</ref>
<ref id="bibr45-0003319711436248">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Waring</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>CB</given-names>
</name>
</person-group>. <article-title>Abdominal obesity and peripheral vascular disease in men and women: a comparison of waist-to-thigh ratio and waist circumference as measures of abdominal obesity</article-title>. <source>Atherosclerosis</source>. <year>2010</year>;<volume>208</volume>(<issue>1</issue>):<fpage>253</fpage>–<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr46-0003319711436248">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jakovljević</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stojanov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lović</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Paunović</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Radosavljević</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Tutić</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Obesity and fat distribution as predictors of aortoiliac peripheral arterial disease in middle-aged men</article-title>. <source>Eur J Intern Med</source>. <year>2011</year>;<volume>22</volume>(<issue>1</issue>):<fpage>84</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr47-0003319711436248">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giugliano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brevetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Laurenzano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brevetti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Luciano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chiariello</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The prognostic impact of general and abdominal obesity in peripheral arterial disease</article-title>. <source>Int J Obes (Lond)</source>. <year>2010</year>;<volume>34</volume>(<issue>2</issue>):<fpage>280</fpage>–<lpage>286</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>